Regular Article
Allelic Loss on Chromosome Arm 8p: Analysis of Sporadic Epithelial Ovarian Tumors

https://doi.org/10.1006/gyno.1999.5439Get rights and content

Abstract

Objective. Our objective was to determine the frequency of allelic loss at 8p21 in sporadic epithelial ovarian cancer. We recently described allelic loss at this locus in 7/9 ovarian cancers from patients with BRCA1 gene mutations.

Methods. We anonymously obtained and examined 40 unselected invasive epithelial ovarian cancers and 5 low-malignant-potential (LMP) ovarian tumors for loss of heterozygosity (LOH) at 8p12–22. Pure epithelial and stromal cell populations were procured selectively by laser capture microdissection and extracted DNA was amplified with polymorphic microsatellite markers spanning the region of interest.

Results. LOH was highest (50%) at marker D8S136 located at 8p21 with 15 of 30 informative cases exhibiting an allelic deletion. None of the LMP tumors evaluated showed LOH at 8p12–22. A trend toward more frequent LOH at 8p12–22 was identified with increasing disease aggressiveness from LMP to early stage invasive ovarian cancer to advanced stage invasive ovarian cancer (Lehman's test, P2 < 0.024).

Conclusions. Fifty percent allelic loss at the distal portion of 8p21 has not been reported to date for sporadic epithelial ovarian carcinomas. The higher rate of loss in our cohort, in contrast to previous allelotyping studies, is due likely to analysis from homogenous cell populations. These results, in concert with our previous study of BRCA1 mutation-positive patients, suggest a tumor suppressor gene locus at 8p21 for epithelial ovarian cancer.

References (27)

  • A Bicher et al.

    Loss of heterozygosity in human ovarian cancer on chromosome 19q

    Gynecol Oncol

    (1997)
  • SH Landis et al.

    Cancer statistics

    CA Cancer J Clin

    (1998)
  • PA Futreal et al.

    BRCA1 mutations in primary breast and ovarian cancers

    Science

    (1994)
  • JM Lancaster et al.

    BRCA2 mutations in primary breast and ovarian cancers

    Nat Genet

    (1996)
  • JR Marks et al.

    Overexpression and mutation of p53 in epithelial ovarian cancer

    Cancer Research

    (1991)
  • M Mandai et al.

    Mutation of the NM23 gene, loss of hetetozygosity at the NM23 locus and K-ras mutation in ovarian carcinoma: correlation with tumor progression and NM23 gene expression

    Br J Cancer

    (1995)
  • JM Freije et al.

    NM23 and tumour metastasis: basic and translational advances

    Biochem Soc Symp

    (1998)
  • J Zheng et al.

    Distinction of low grade from high grade human ovarian carcinomas on the basis of loss of heterozygosity on chromosomes 3, 6, and 11 and Her-2/neu gene amplification

    Cancer Res

    (1991)
  • MI Edelson et al.

    Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas

    Oncogene

    (1997)
  • I Cooke et al.

    Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer

    Genes Chromosomes Cancer

    (1996)
  • MR Emmert-Buck et al.

    Allelic loss on chromosome 8p in BRCA1 mutation positive breast/ovarian cancers

    Breast J

    (1998)
  • RJ Osborne et al.

    Polymerase chain allelotyping of human ovarian cancer

    Br J Cancer

    (1994)
  • W Cliby et al.

    Human epithelial cancer allelotype

    Cancer Res

    (1993)
  • Cited by (50)

    • PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation

      2009, Blood
      Citation Excerpt :

      Currently, the mechanism by which PDLIM2 gene is suppressed in cancer cells is unknown. One clue is the genomic location of PDLIM2, 8p21, which frequently undergoes allelic loss in ovarian and prostate cancers.47,48 Another possibility is epigenetic suppression of PDLIM2, as PDLIM4, a family member of PDLIM2 that shows tumor suppression function, is repressed by DNA methylation in many cancers.49

    • Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT

      2007, Gynecologic Oncology
      Citation Excerpt :

      CSOC 882 cells also possess a deletion of 8p21. Deletions of 8p21 have been observed previously and are associated with increased malignant potential [15]. We find it of considerable interest that the 4EBP1 gene is located at 8p21.

    View all citing articles on Scopus
    1

    To whom correspondence and reprint requests should be addressed at National Cancer Institute, Building 10, Room 2A33, 10 Center Drive, MDC 1500, Bethesda, MD 20892-1500. Fax: (301) 480-5142.

    View full text